Financhill
Buy
58

SMMT Quote, Financials, Valuation and Earnings

Last price:
$23.97
Seasonality move :
6.57%
Day range:
$23.96 - $25.79
52-week range:
$2.10 - $36.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18,760.17x
P/B ratio:
53.17x
Volume:
2.9M
Avg. volume:
5.5M
1-year change:
396.98%
Market cap:
$18.3B
Revenue:
--
EPS (TTM):
-$0.35

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SMMT
Summit Therapeutics
-- -$0.09 -- -1.36% $37.31
IVVD
Invivyd
$34.5M -$0.01 1421.66% -97.37% $6.60
LLY
Eli Lilly and
$12.7B $3.46 26.74% 68.13% $981.63
MRK
Merck &
$15.3B $2.14 -1.55% -4.03% $105.02
PFE
Pfizer
$14.1B $0.67 1.01% 5555.3% $29.25
VKTX
Viking Therapeutics
-- -$0.31 -- -120.34% $90.26
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SMMT
Summit Therapeutics
$24.65 $37.31 $18.3B -- $0.00 0% 18,760.17x
IVVD
Invivyd
$0.59 $6.60 $70.8M -- $0.00 0% --
LLY
Eli Lilly and
$751.45 $981.63 $674.6B 61.14x $1.50 0.72% 13.85x
MRK
Merck &
$77.65 $105.02 $195B 11.30x $0.81 4.07% 3.08x
PFE
Pfizer
$22.97 $29.25 $130.6B 16.64x $0.43 7.36% 2.10x
VKTX
Viking Therapeutics
$27.85 $90.26 $3.1B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SMMT
Summit Therapeutics
-- 5.431 -- --
IVVD
Invivyd
-- -3.264 -- 1.30x
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
MRK
Merck &
41.89% 0.358 16.34% 0.80x
PFE
Pfizer
40.42% 0.423 42.46% 0.88x
VKTX
Viking Therapeutics
-- -0.956 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SMMT
Summit Therapeutics
-- -$66.9M -- -- -- -$61.6M
IVVD
Invivyd
$13.1M -$19.2M -- -- -139.14% -$37.6M
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
MRK
Merck &
$12.1B $5.9B 21.5% 39.02% 40.03% $1.2B
PFE
Pfizer
$10.9B $4.4B 5.05% 8.72% 25.08% $1.8B
VKTX
Viking Therapeutics
-- -$55.5M -- -- -- -$31.2M

Summit Therapeutics vs. Competitors

  • Which has Higher Returns SMMT or IVVD?

    Invivyd has a net margin of -- compared to Summit Therapeutics's net margin of -133.45%. Summit Therapeutics's return on equity of -- beat Invivyd's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SMMT
    Summit Therapeutics
    -- -$0.09 --
    IVVD
    Invivyd
    94.76% -$0.15 $67.5M
  • What do Analysts Say About SMMT or IVVD?

    Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.52%. On the other hand Invivyd has an analysts' consensus of $6.60 which suggests that it could grow by 1018.64%. Given that Invivyd has higher upside potential than Summit Therapeutics, analysts believe Invivyd is more attractive than Summit Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SMMT
    Summit Therapeutics
    7 0 0
    IVVD
    Invivyd
    1 1 0
  • Is SMMT or IVVD More Risky?

    Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Invivyd has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SMMT or IVVD?

    Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Invivyd pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SMMT or IVVD?

    Summit Therapeutics quarterly revenues are --, which are smaller than Invivyd quarterly revenues of $13.8M. Summit Therapeutics's net income of -$62.9M is lower than Invivyd's net income of -$18.4M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Invivyd's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,760.17x versus -- for Invivyd. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SMMT
    Summit Therapeutics
    18,760.17x -- -- -$62.9M
    IVVD
    Invivyd
    -- -- $13.8M -$18.4M
  • Which has Higher Returns SMMT or LLY?

    Eli Lilly and has a net margin of -- compared to Summit Therapeutics's net margin of 21.68%. Summit Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    SMMT
    Summit Therapeutics
    -- -$0.09 --
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About SMMT or LLY?

    Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.52%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 30.63%. Given that Summit Therapeutics has higher upside potential than Eli Lilly and, analysts believe Summit Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    SMMT
    Summit Therapeutics
    7 0 0
    LLY
    Eli Lilly and
    15 3 1
  • Is SMMT or LLY More Risky?

    Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

  • Which is a Better Dividend Stock SMMT or LLY?

    Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Summit Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SMMT or LLY?

    Summit Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Summit Therapeutics's net income of -$62.9M is lower than Eli Lilly and's net income of $2.8B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,760.17x versus 13.85x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SMMT
    Summit Therapeutics
    18,760.17x -- -- -$62.9M
    LLY
    Eli Lilly and
    13.85x 61.14x $12.7B $2.8B
  • Which has Higher Returns SMMT or MRK?

    Merck & has a net margin of -- compared to Summit Therapeutics's net margin of 32.71%. Summit Therapeutics's return on equity of -- beat Merck &'s return on equity of 39.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    SMMT
    Summit Therapeutics
    -- -$0.09 --
    MRK
    Merck &
    77.98% $2.01 $83.2B
  • What do Analysts Say About SMMT or MRK?

    Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.52%. On the other hand Merck & has an analysts' consensus of $105.02 which suggests that it could grow by 35.25%. Given that Summit Therapeutics has higher upside potential than Merck &, analysts believe Summit Therapeutics is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    SMMT
    Summit Therapeutics
    7 0 0
    MRK
    Merck &
    12 11 0
  • Is SMMT or MRK More Risky?

    Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

  • Which is a Better Dividend Stock SMMT or MRK?

    Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.07% to investors and pays a quarterly dividend of $0.81 per share. Summit Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SMMT or MRK?

    Summit Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Summit Therapeutics's net income of -$62.9M is lower than Merck &'s net income of $5.1B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,760.17x versus 3.08x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SMMT
    Summit Therapeutics
    18,760.17x -- -- -$62.9M
    MRK
    Merck &
    3.08x 11.30x $15.5B $5.1B
  • Which has Higher Returns SMMT or PFE?

    Pfizer has a net margin of -- compared to Summit Therapeutics's net margin of 21.63%. Summit Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    SMMT
    Summit Therapeutics
    -- -$0.09 --
    PFE
    Pfizer
    79.26% $0.52 $151.9B
  • What do Analysts Say About SMMT or PFE?

    Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.52%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 27.33%. Given that Summit Therapeutics has higher upside potential than Pfizer, analysts believe Summit Therapeutics is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    SMMT
    Summit Therapeutics
    7 0 0
    PFE
    Pfizer
    6 15 1
  • Is SMMT or PFE More Risky?

    Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

  • Which is a Better Dividend Stock SMMT or PFE?

    Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Summit Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios SMMT or PFE?

    Summit Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Summit Therapeutics's net income of -$62.9M is lower than Pfizer's net income of $3B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,760.17x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SMMT
    Summit Therapeutics
    18,760.17x -- -- -$62.9M
    PFE
    Pfizer
    2.10x 16.64x $13.7B $3B
  • Which has Higher Returns SMMT or VKTX?

    Viking Therapeutics has a net margin of -- compared to Summit Therapeutics's net margin of --. Summit Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SMMT
    Summit Therapeutics
    -- -$0.09 --
    VKTX
    Viking Therapeutics
    -- -$0.41 --
  • What do Analysts Say About SMMT or VKTX?

    Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.52%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 224.11%. Given that Viking Therapeutics has higher upside potential than Summit Therapeutics, analysts believe Viking Therapeutics is more attractive than Summit Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SMMT
    Summit Therapeutics
    7 0 0
    VKTX
    Viking Therapeutics
    10 2 0
  • Is SMMT or VKTX More Risky?

    Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

  • Which is a Better Dividend Stock SMMT or VKTX?

    Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SMMT or VKTX?

    Summit Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Summit Therapeutics's net income of -$62.9M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,760.17x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SMMT
    Summit Therapeutics
    18,760.17x -- -- -$62.9M
    VKTX
    Viking Therapeutics
    -- -- -- -$45.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 9.31% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 9.61% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock